LEADS BIOLABS-B(09887): The first patient in the phase IB/II trial of LBL-024 for platinum-resistant ovarian cancer.

LEADS BIOLABS-B(09887) announced that the first patient in the phase Ib/II clinical study evaluating the use of the PD-L1/4-1BB bispecific antibody (LBL-024) for the treatment of platinum-resistant ovarian cancer has successfully received treatment. This open-label, multicenter phase Ib/II clinical study is led by Professor Wu Lingying from the Cancer Hospital of the Chinese Academy of Medical Sciences, and is being conducted simultaneously in multiple hospitals across the country. The trial aims to evaluate the efficacy and safety of the combination of the PD-L1/4-1BB bispecific antibody with paclitaxel in the treatment of patients with platinum-resistant ovarian cancer.